Glucose utilization via glycogen phosphorylase sustains proliferation and prevents premature senescence in cancer cells. by Favaro, E et al.
Cell Metabolism
ArticleGlucose Utilization via Glycogen Phosphorylase
Sustains Proliferation and
Prevents Premature Senescence in Cancer Cells
Elena Favaro,1 Karim Bensaad,1 Mei G. Chong,2 Daniel A. Tennant,2 David J.P. Ferguson,3 Cameron Snell,3
Graham Steers,3 Helen Turley,3 Ji-Liang Li,1 Ulrich L. Gu¨nther,2 Francesca M. Buffa,1 Alan McIntyre,1
and Adrian L. Harris1,*
1Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital,
Oxford OX3 9DS, UK
2School of Cancer Sciences, University of Birmingham, Birmingham B15 2TT, UK
3Nuffield Department of Clinical Laboratory Sciences, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, UK
*Correspondence: adrian.harris@oncology.ox.ac.uk
http://dx.doi.org/10.1016/j.cmet.2012.10.017SUMMARY
Metabolic reprogramming of cancer cells provides
energy and multiple intermediates critical for cell
growth. Hypoxia in tumors represents a hostile envi-
ronment that can encourage these transformations.
We report that glycogen metabolism is upregulated
in tumors in vivo and in cancer cells in vitro in
response to hypoxia. In vitro, hypoxia induced an
early accumulation of glycogen, followed by a
gradual decline. Concordantly, glycogen synthase
(GYS1) showed a rapid induction, followed by a later
increase of glycogen phosphorylase (PYGL). PYGL
depletion and the consequent glycogen accumula-
tion led to increased reactive oxygen species (ROS)
levels that contributed to a p53-dependent induction
of senescence andmarkedly impaired tumorigenesis
in vivo. Metabolic analyses indicated that glycogen
degradation by PYGL is important for the optimal
function of the pentose phosphate pathway. Thus,
glycogen metabolism is a key pathway induced by
hypoxia, necessary for optimal glucose utilization,
which represents a targetable mechanism of meta-
bolic adaptation.
INTRODUCTION
A fundamental property of cancer cells is that they undergo
metabolic reprogramming in response to the hypoxic environ-
ment present in solid tumors. Cancer cells rely primarily on
aerobic glycolysis to sustain their proliferation (Lunt and Vander
Heiden, 2011). The increased uptake andmetabolism of glucose
even in the presence of oxygen is known as the ‘‘Warburg effect’’
(Warburg, 1956). This is a relatively inefficient way to generate
ATP (2 ATPs per glucose) as compared to oxidative phosphory-
lation (36 ATPs per glucose), and it contributes to only 17%of the
total ATP production (Zu and Guppy, 2004), suggesting other
critical roles for aerobic glycolysis. Indeed, many observationsCell Mhave proposed a role for glycolysis in providing precursors for
anabolic pathways (e.g., lipids, nucleotides, and amino acids),
as well as cofactors (e.g., NADH and NADPH), which are
required for cancer cell proliferation (Ward and Thompson,
2012). To address the effect of the hypoxic microenvironment
onmetabolic pathways, we used an in vivomodel in which xeno-
grafts of U87 glioblastoma cells were treated with the antiangio-
genic drug bevacizumab, and the gene expression profile was
compared to untreated tumors. Several established HIF-targets
(including CA9 [Wykoff et al., 2000]) were upregulated, reflecting
the increase in intratumoral hypoxia. Moreover, numerous meta-
bolic pathways were modulated. One of these was glycogen
metabolism.
Glycogen comprises a store of glucose, which is mainly
present in liver and muscles. The structure consists of long poly-
meric chains of glucose units linked by alpha (a)-1,4 glycosidic
bonds with occasional a-1,6 glycosidic bonds that generate
branching points and increase solubility (Berg et al., 2002).
Synthesis and breakdown of glycogen involves the activity
of several enzymes and regulatory proteins. Among these,
glycogen synthase (GS) and glycogen phosphorylase (GP) cata-
lyze the key steps of synthesis and degradation, respectively
(see Figure S1A online) (Berg et al., 2002). GS elongates gly-
cogen branches through the formation of a-1,4 glycosidic
bridges, whereas GP cleaves these, releasing glucose-1-phos-
phate (G1P) that can enter the glycolytic pathway or the pentose
phosphate pathway (PPP) by conversion to glucose-6-phos-
phate (G6P). GS has two isoforms: GYS1 (muscle) and GYS2
(liver) (Roach et al., 1998). GP has three: PYGM (muscle),
PYGL (liver), and PYGB (brain) (Newgard et al., 1989). The
activity of these enzymes can be modulated by posttranslational
modification (e.g., phosphorylation, stimulated by the hormones
glucagon and epinephrine, which have inhibitory and activating
effects on GS and GP, respectively) and allosteric effectors
(ATP, AMP, and G6P) (Johnson, 1992; Lawrence and Roach,
1997).
A number of observations have suggested that the turnover of
glycogen is altered in tumor cells. The levels of glycogen were
demonstrated to be particularly high in breast, kidney, uterus,
bladder, ovary, skin, and brain cancer cell lines. Glycogen
content in these cells was inversely correlated with proliferationetabolism 16, 751–764, December 5, 2012 ª2012 Elsevier Inc. 751
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hypoxic conditions has also been observed in several noncancer
and cancer cell lines (Mamedova et al., 2003; Pelletier et al.,
2012; Pescador et al., 2010; Shen et al., 2010; Vigoda et al.,
2003). Consistent with these observations, GYS1 and other
proteins involved in glycogen synthesis are induced in hypoxia
in a HIF1a-dependent manner (Mole et al., 2009; Pelletier
et al., 2012; Pescador et al., 2010; Shen et al., 2010). PYGL
was included in a list of 99 genes defining the hypoxia ‘‘meta-
gene,’’ a signature defined in vivo in head and neck squamous
cell carcinomas (HNSCCs) by clustering genes with similar
expression patterns to that of well-characterized hypoxia-regu-
lated genes (Winter et al., 2007). This signature proved to be
prognostic in independent HNSCC and breast cancer series.
Recent studies have suggested a critical role of glycogen in
promoting the survival of cancer cells. In particular, it has been
demonstrated that a small molecule inhibitor of glycogen break-
down could induce apoptosis in pancreatic tumor cells (Lee
et al., 2004). Furthermore, it has been shown by two independent
studies that glycogen accumulation in cancer cells improves
survival in response to low oxygen concentration and glucose
deprivation (Pelletier et al., 2012; Pescador et al., 2010). Taken
together, these observations suggested a role for glycogen in
promoting tumor growth in hypoxic environments.
In this study, we further characterized the roles of glycogen-
metabolizing enzymes in cancer cell biology. We demonstrate
that glycogen levels undergo dramatic temporal changes in
cancer cells exposed to hypoxic stress. Furthermore, we show
that PYGL depletion (and consequent glycogen accumulation)
induces premature senescence via a ROS-dependent mecha-
nism, reduces the input into the PPP, and strongly impairs
tumor growth. Surprisingly, glucose utilization via glycogen,
rather than direct entry into downstream pathways, is neces-
sary for optimum growth. Our study reveals an important contri-
bution of glycogen metabolism to cancer cell proliferation,
survival, and free radical protection in the context of metabolic
reprogramming.
RESULTS
Glycogen-Metabolizing Genes Are Upregulated by
Antiangiogenic Treatment
We focused our analyses on U87 (glioblastoma), MCF-7 (breast),
and HCT116 (colon) cancer cell lines, as previous studies have
shown elevated levels of glycogen in these cell lines (Rousset
et al., 1981). To further identify the metabolic pathways required
for the survival of tumor cells in hypoxic environments, we
analyzed the gene expression profile of xenografts of the glio-
blastoma cell line U87 treated with the VEGF inhibitor bevacizu-
mab. After chronic administration of bevacizumab, these tumors
were characterized by regrowth and development of resistance
to the treatment.
We observed that carbonic anhydrase IX (CA9), which is an
indicator of HIF1a activation (Wykoff et al., 2000), was upregu-
lated in bevacizumab-treated tumors, as compared to control
tumors (Figure 1A). A number of genes implicated in glycogen
metabolism (e.g., protein phosphatase 1, regulatory subunit 3B
[PPP1R3B]; glycogen synthase 1 [GYS1]; acid a-glucosidase
[GAA]; protein phosphatase 1, regulatory subunit 3C [PPP1R3C];752 Cell Metabolism 16, 751–764, December 5, 2012 ª2012 Elsevierliver glycogen phosphorylase [PYGL]; glycogen branching
enzyme 1 [GBE1]; Genethonin-1 [GENX-3414]; and phosphoglu-
comutase 1 [PGM1]) were similarly upregulated (Figure 1A and
Figure S1A). The expression of GYS1 and PYGL, which encode
for the two main enzymes implicated in glycogen storage
(GYS1) and breakdown (PYGL), were increased by 4.1- and
2.6-fold, respectively. We therefore focused our analyses on
GYS1 and PYGL because of their central roles in glycogen
metabolism. Increased expression of CA9, GYS1, and PYGL
was confirmed at the mRNA level by RT-PCR (Figure 1B). Stain-
ing of serial sections revealed an increase in levels of the hypoxia
marker pimonidazole (30.6% ± 4%versus 12.7%± 3.9%), GYS1
(27.8% ± 1.4% versus 14.3% ± 3.7%), PYGL (69.9% ± 7%
versus 37.7% ± 7.2%) and more than a 10-fold increase in
glycogen, as detected by Periodic Acid-Schiff (PAS) staining
(5.3% ± 2% versus 0.4% ± 0.2%) in bevacizumab-treated
tumors (Figure S1B). A positive correlation between glycogen
levels and hypoxia was also supported by colocalization of
CA9 and PAS staining in the perinecrotic area of treated
tumors (Figure 1C). Moreover, immunohistochemical analysis
of HCT116 spheroids revealed that GYS1 and PYGL staining
was more pronounced in (pimonidazole-positive) hypoxic cells
(Figure 1D). Collectively, these results indicate that glycogen
metabolism increases with hypoxia in tumors and spheroids.
Hypoxia Induces the Expression of GYS1 and PYGL and
Causes Characteristic Changes in Glycogen
Metabolism
To further investigate the roles of GYS1 and PYGL and their
association with hypoxia, we examined their expression in
cancer cell lines cultivated in vitro. Analysis of GYS1 and PYGL
expression in U87 cells revealed distinct patterns of induction
by hypoxia (0.1% O2) that were consistent at both the mRNA
(Figure 2A) and protein level (Figure 2B). We observed that
GYS1 levels increased rapidly in hypoxia, and then declined by
72 hr, whereas PYGL levels increased more slowly in hypoxia,
and reached maximal levels at 72 hr. These findings were also
confirmed in MCF-7 and HCT116 cell lines (Figures S2A and
S2B). Glycogen synthesis through GYS1 requires intracellular
availability of the allosteric activator G6P (Bouskila et al.,
2010). We observed hypoxic induction of the glucose transporter
GLUT1 and the glucose-phosphorylating enzyme hexokinase II
(HKII) (Figure 2B), both of which have been previously character-
ized as HIF-target genes (Semenza, 2002). GYS1 is inhibited by
phosphorylation (Lawrence and Roach, 1997); therefore, protein
activity can bemeasured by comparing the ratio of phosphoryla-
ted:nonphosphorylated GYS1. Interestingly, we observed that
after an initial decrease (12 hr), the level of phosphorylated
GYS1 increased after 24 hr in hypoxia and remained constant
from 24 to 72 hr in hypoxia, despite a time-dependent decrease
in total GYS1 levels (Figure 2B). This suggests that a higher
proportion of GYS1 is phosphorylated/inactivated in hypoxia at
later time points.
We note that two other isoforms of PYGL also exist in human
cells, PYGM and PYGB. However, we observed that, unlike
PYGL, neither of these genes exhibited a detectable/significant
hypoxia-induced increase in U87 cells (data not shown). There-
fore, PYGL was likely to be the main GP activity required for
glycogen breakdown in hypoxic cells.Inc.
Figure 1. Glycogen Metabolism Is Modulated after Bevacizumab Treatment
(A) List of genes involved in glycogen metabolism, found to be upregulated in U87 xenografts treated with bevacizumab compared to controls.
(B) RT-PCR for CA9, GYS1, and PYGL in U87 xenografts treated with bevacizumab. Relative expression of GYS1 and PYGL is normalized to b-actin. Mean
expression ± SEM in four animals/group is shown (**p < 0.01, ***p < 0.001).
(C) Serial sections derived from bevacizumab-treated U87 xenografts were stained for CA9 (left panel) and glycogen (PAS, middle panel) and costained for CA9
and glycogen (right panel). Two different magnifications are shown. N, necrosis.
(D) Haematoxylin and eosin (H&E) staining (left panels), and immunohistochemical staining of HCT116-derived spheroid. Serial sections were stained for
pimonidazole (middle panels), GYS1 (top right panel), or PYGL (bottom right panel). N, necrosis. See also Figure S1.
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Figure 2. Pattern of GYS1 and PYGL Induction and Changes on Glycogen Level under Hypoxia
(A and B) In U87 cells, GYS1 expression is induced rapidly (12 hr) in hypoxia and starts to decrease at the later time points (72 hr), whereas PYGL expression
follows a more delayed pattern of induction, with maximal expression at the later time points (72 hr). Shown are mRNA levels (A) and protein expression by
immunoblotting (B) after 0, 12, 24, 48, or 72 hr in hypoxia. Levels of GYS1 and PYGL mRNA under hypoxia are relative to their levels at 0 hr. Mean ± SEM of three
independent experiments is shown (*p < 0.05, **p < 0.01, ***p < 0.001). (C) Glycogen accumulation in hypoxia was measured by enzymatic assay in U87 cells
exposed to hypoxia in a time course experiment. Glycogen was normalized by protein content. Mean ± SEM of three independent experiments is shown (*p <
0.05, ***p < 0.001). PAS staining (D) showing strong staining in the hypoxia-treated section, confirmed to be glycogen by the absence of staining after amylase
pretreatment, and TEM (E) showing lucent pools of glycogen (G) in the hypoxic cells. U87 were exposed to hypoxia for 48 hr. N, normoxia; H, hypoxia. (F)
Glycogen accumulation (G) was detected by specific staining for polysaccharides using an adaptation of the PATO method. See also Figures S2 and S3.
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PYGL Sustains Cancer Cell ProliferationWe observed that glycogen levels underwent a rapid increase,
which peaked by 24 hr (598 ± 57 versus 52 ± 3 ng [glucose]/mg
[protein]), and then gradually declined by 72 hr (216 ±
67 ng/mg) (Figure 2C). A similar pattern of glycogen metabolism
alteration was also detected in MCF-7 cells (Figure S2C).
Increased glycogen levels after 48 hr incubation of U87 cells in
hypoxia were also confirmed by PAS staining and by trans-
mission electron microscopy (TEM) (Figures 2D and 2E). TEM
staining for polysaccharide material using the periodic acid-thio-
carbohydrazide-osmium tetroxide (PATO) method (Ferguson
et al., 1977) revealed electron-dense stain deposits both within
and at the periphery of the irregular-shaped cytoplasmic struc-
tures, confirming that the lucent structures observed by routine
electron microscopy contain glycogen (Figure 2F). Furthermore,
similar structures were observed by TEM, when glycogen syn-
thesis was induced in U87 cells with a glycogen synthase kinase
3 (GSK3) inhibitor (CHIR99021) (Ring et al., 2003) (Figure S2D).
Hypoxic induction of other glycogen metabolism enzymes
(e.g., GAA and GBE) and regulatory proteins (e.g., PPP1R3B
and PPP1R3C) identified from our initial analysis of bevacizu-
mab-treated tumors (Figure 1A) was also confirmed in U87 cells
by qPCR (Figure S2E). In particular, the lysosomal glycogenolytic
GAA enzyme mRNA levels peaked at 72 hr, similarly to PYGL,
whereas the branching enzymeGBE and the glycogenic proteins
PPP1R3B and PPP1R3C exhibited an initial rapid increase in
mRNA levels, followed by a decline by 72 hr, similar to what
was observed for GYS1 induction.
To test the possibility that glycogen accumulation in hypoxia
could be a consequence of the high glucose concentration
(25 mM) present in standard culture media, we examined the
consequences of lowering the glucose concentration to physio-
logical blood levels (5 mM). We observed a pattern of GYS1 and
PYGL induction and glycogen accumulation similar to that
observed in high-glucose conditions in U87 cells (Figure S2F).
Therefore, glycogen accumulation in hypoxia is not simply a
consequence of high extracellular glucose concentration.
The hypoxic induction of GYS1 and PYGL led us to investigate
the contribution of HIF1a. HIF-dependent regulation was evalu-
ated in U87 and MCF-7 cells at the peak of hypoxic induction
(48 hr for GYS1 mRNA and 72 hr for PYGL mRNA [Figures 2A
and 2B, Figure S2A]). In agreement with recent reports (Mole
et al., 2009; Pescador et al., 2010), we observed that HIF1a
depletion in U87 and MCF-7 cells prevented GYS1 induction in
hypoxia (Figures S3A and S3B). Conversely, HIF-dependent
induction of PYGL was not consistently observed in these cell
lines and probably occurs indirectly in MCF-7 cells (Figures
S3A and S3B). A previous report on genome-wide analysis of
HIFa DNA binding in MCF-7 cells using chromatin immunopre-
cipitation did not reveal any PYGL promoter binding (Mole
et al., 2009). These findings suggest that PYGL induction in
hypoxia is unlikely to be HIF dependent.
PYGL Is Upregulated in Several Cancer Types
PYGL is one of the 99 genes defining the hypoxia ‘‘metagene,’’
a gene signature derived from HNSCC, with poor prognostic
outcome both in HNSCC and breast cancer (Winter et al.,
2007). The Oncomine website (https://www.oncomine.org/)
was queried for microarrays containing PYGL. A meta-analysis
on over 2,000 cases showed that PYGL is upregulated in severalCell Mcancer types, including clear cell renal carcinoma, papillary renal
cell carcinoma, seminoma, and brain cancer (Figures S4A and
S4B, Table S1), as compared to normal tissues. Furthermore,
none of the studies examined thus far exhibited any downregu-
lation of PYGL. Taken together, these findings suggested that
the study of PYGL functions in hypoxia could have important
clinical considerations. To analyze the levels of PYGL during
various stages of tumor development, we utilized the Her-2/
neu transgenic mouse model of breast cancer. In this model,
the expression of neu, the rat homolog of the epidermal growth
factor receptor Her-2, is controlled by the mouse mammary
tumor virus-long terminal repeat (MMTV-LTR) promoter. These
transgenic mice develop tumors that are morphologically similar
to human ductal breast carcinomas (Ursini-Siegel et al., 2007).
We therefore analyzed four tumor samples of different size
(4, 6, 8, and 10 mm diameter) as representative tumors at
different stages of development. Increased PYGL levels, as
detected by immunostaining, were associated with increased
tumor size, suggesting that PYGL is associated with tumor
progression (Figure S4C).
PYGL Knockdown Is Associated with Glycogen
Accumulation and Premature Senescence
To analyze the consequences of PYGL depletion in tumor cells,
we then generated transient or stable PYGL knockdown U87
cells using RNA interference (RNAi). For this, we utilized multiple
RNA sequences, each directed against a different site of the
PYGL transcript. In both cases, the hypoxic induction of PYGL
was prevented (Figure S4D), and this was associated with
more pronounced glycogen accumulation in hypoxia (Fig-
ure 3A). Importantly, GYS1 levels were unaffected by PYGL
knockdown (Figure 3B), suggesting that glycogen accumulation
after 48 and 72 hr was a direct consequence of PYGL depletion.
The accumulation of glycogen was also confirmed at 48 hr
by measuring incorporation of the fluorescent glucose analog
2-NBDG into glycogen granules, by PAS staining, and by TEM
(Figure 3C).
Depletion of PYGL was also associated with a significant re-
duction of U87 cell numbers after 48–72 hr exposure to hypoxia
(Figure 4A). Furthermore, we verified that PYGL knockdown
increased glycogen content and inhibited cell growth in the
presence of lower (5 mM) glucose, confirming the physiological
relevance of our findings (Figure S4E). The effects of PYGL
knockdown were also confirmed by decreased clonogenic sur-
vival in MCF-7 cells under hypoxia (70.2% ± 4.1% compared
to control in hypoxia) (Figure S4F). We note that PYGL depletion
causes similar, albeit milder, effects in normoxic cells (Fig-
ure S4G). We conclude that PYGL depletion causes glycogen
accumulation and decreased growth rate of cancer cell lines,
and this phenotype is exacerbated in hypoxia.
To investigate the mechanism underlying this growth defect,
we analyzed the effects of PYGL knockdown on cell viability.
Analysis of Annexin V-positive cells and PARP cleavage showed
only a minimal effect, suggesting that PYGL-depleted cells did
not undergo apoptosis (Figure S4H). Analysis of the cell-cycle
profile after PYGL knockdown in U87 cells revealed a higher
proportion of cells in G1 phase with concomitant decreases in
both S phase and G2/M phase, as compared to control cells
(Figure 4B). This was associated with increased levels of theetabolism 16, 751–764, December 5, 2012 ª2012 Elsevier Inc. 755
Figure 3. PYGL Knockdown Results in Glycogen Accumulation
(A) U87 were exposed to hypoxia in a time course experiment. Depletion of PYGL showed increased accumulation of glycogen compared to control after 48 and
72 hr in U87 shPYGL cells and after 24, 48, and 72 hr in U87 siPYGL pool cells. Glycogen content was normalized by cell number. Mean ± SEM of three
independent experiments is shown (*p < 0.05, **p < 0.01).
(B) GYS1 protein is similarly expressed in U87 shCtrl and shPYGL cells after 48 or 72 hr in hypoxia.
(C) Glycogen accumulation in PYGL knockdown and control cells exposed to 0.1%O2 for 48 hr was detected with the green fluorescent dye 2-NBDG (top panels),
PAS staining (middle panels), and TEM (bottom panels). G, glycogen. See also Figure S4.
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et al., 1993) (Figure 4C). To test if p53 induction was responsible
for the decreased growth rate caused by PYGL knockdown, we
investigated the effects of simultaneously depleting PYGL and
p53. Knockdown of p53 prevented the decreased growth rate
phenotype normally associated with PYGL depletion (Figures
4C and 4D).
Following PYGL depletion, U87 cells underwent characteristic
morphological changes (i.e., enlargement and flattening) that
were indicative of cellular senescence (Figure 5A). In addition756 Cell Metabolism 16, 751–764, December 5, 2012 ª2012 Elsevierto a G1 cell-cycle arrest, and increased levels of p53 and p21
(Figures 4B and 4C), increased expression of DEC1 (Collado
et al., 2005; Schmitt, 2007) and an increased activity of senes-
cence-associated b-galactosidase (SA b-gal), which correlates
with an increase in lysosomal content (Kurz et al., 2000; Schmitt,
2007), have also been reported to be well-established markers
for cellular senescence. Following PYGL knockdown, we ob-
served an increase in both DEC1 and SA b-gal staining (Figures
5B and 5C and Figure S4I). After staining the cells with
LysoTracker red, a dye that is selectively incorporated intoInc.
Figure 4. PYGL Sustains Proliferation in Cancer Cell Lines
(A) PYGL knockdown in U87 cells resulted in reduction of proliferation after 48 hr (shPYGL) or 24 hr (siPYGL pool) in hypoxia. Mean ± SEM of three independent
experiments is shown (*p < 0.05).
(B) PYGL depletion in U87 cells was associatedwith increasedG1 phase and decreased S andG2/Mphases of the cell cycle. Cells were cultivated in normoxia (N)
or hypoxia (H) for 48 hr. Mean ± SEM of three independent experiments is shown (*p < 0.05, **p < 0.01).
(C) Immunoblotting for the cell-cycle regulators p21 and p53 revealed increased levels after PYGL depletion at 48 hr hypoxia.
(D) Under the same conditions, combined knockdown of PYGL and p53 prevented cell growth arrest observed with PYGL knockdown only. Mean ± SEM of three
independent experiments is shown (*p < 0.05). See also Figures S4 and S5.
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especially in hypoxia (Figure 5D). In support of this observation,
TEM images also revealed an accumulation of vacuoles in the
cytosol of PYGL-depleted U87 cells, as compared to normoxia
and control cells in hypoxia (Figure 5D). Finally, we also detected
increased expression levels of GAA, consistent with increased
lysosomal activity in PYGL-depleted cells (Figure 5E). Taken
together, our data indicate that PYGL depletion results in ele-
vated glycogen accumulation in hypoxia and reduced prolifera-
tion due to p53-induced premature senescence.
To further examine the relationship between glycogen accu-
mulation and induction of senescence in PYGL-depleted cells,
we analyzed the phenotypic consequences of simultaneousCell MGYS1 and PYGL knockdown. Because GYS1 knockdown was
detrimental to MCF-7 and HCT116 cells (Figure S5A) but better
tolerated in U87 cells (Figure S5C), we performed the GYS1
and PYGL codepletion studies in this cell line only (Figure S5B).
We observed that GYS1 depletion, either alone or in conjunction
with the simultaneous knockdown of PYGL, significantly attenu-
ated (but did not completely prevent) glycogen accumulation
that normally occurs in hypoxia (Figure S5C). Furthermore,
GYS1 and PYGL codepleted cells did not exhibit any cell growth
defects in hypoxia, suggesting that a reduction in GYS1-
dependent glycogen accumulation ameliorates the premature
senescence phenotype normally associated with PYGL knock-
down (Figure S5C). Taken together, we propose that glycogenetabolism 16, 751–764, December 5, 2012 ª2012 Elsevier Inc. 757
Figure 5. PYGL Knockdown Promotes
Senescence
(A) Representative images of U87 cells cultivated
in normoxia (N) or hypoxia (H) for 48 hr, displaying
senescence-like morphology when PYGL is
decreased.
(B) Immunohistochemical analysis of DEC1 in
sections of U87 cells treated as in (A). Arrows
indicate representative positive cells.
(C) Senescence-associated b-galactosidase
staining at pH 6 of U87 shCtrl and shPYGL cells
treated as in (A). Senescent cells are colored in
blue upon X-gal staining (left panels). Senescence
in each condition was quantified and expressed as
percentage of SA-b-gal-positive cells (right panel).
Mean expression ± SEM of three independent
experiments is shown (***p < 0.001).
(D) PYGL deficiency was associated with accu-
mulation of lysosomes as shown by LysoTracker
red staining, and vacuoles as shown by TEM
(arrows). On the left panels, nuclei were stained
with DAPI. G, glycogen.
(E) mRNA expression of lysosomal GAA was
measured in U87 cells with decreased PYGL levels
and compared to control cells in normoxia or after
48 hr at 0.1% O2. Mean ± SEM of three indepen-
dent experiments is shown (*p < 0.05, **p < 0.01,
***p < 0.001). See also Figures S4 and S5.
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PYGL knockdown cells. We note, however, that low levels of
GYS1 and PYGL (due to incomplete knockdown) may still be
sufficient for glycogen turnover in U87 cells.
Reactive Oxygen Species Contribute to Premature
Senescence in the Absence of PYGL
Next, we examined the specific cause of premature senescence
in PYGL-depleted cells. Because ROS are recognized contribu-
tors to premature senescence (Kuilman et al., 2010; Lu and Fin-
kel, 2008), we measured the production of mitochondrial super-758 Cell Metabolism 16, 751–764, December 5, 2012 ª2012 Elsevier Inc.oxide in U87 and MCF-7 cells. Both cell
lines showed amarked increase in super-
oxide levels upon transfection of siPYGL
pool (50% ± 6% versus 33% ± 1% in
U87 and 33% ± 4% versus 17% ± 0.5%
in MCF-7) (Figure 6A). When cells were
simultaneously exposed to the cell-per-
meant ROS scavenger manganese (III)
tetrakis (1-methyl-4-pyridyl) porphyrin
(MnTMPyP), the production of super-
oxide was significantly reduced in both
control and siPYGL pool cells (Fig-
ure 6B). Moreover, intracellular ROS, as
measured by generation of dichlorofluor-
esceine (DCF) from 20, 70-dichloro-dihy-
drofluoresceine (H2-DCFDA), showed a
significant higher level in U87 shPYGL
cells, as compared to control cells (Fig-
ure 6C). The reduced cell proliferation
phenotype normally associated with
PYGL depletion was also partially sup-pressed when cells were treated with MnTMPyP (Figure 6D).
We therefore propose that increased ROS levels contribute to
p53-dependent induction of senescence in PYGL-depleted
cells.
Breakdown of glycogen by GP causes the release of G1P
that is then converted to G6P by the enzyme phosphogluco-
mutase, and enters the glycolytic cascade or the PPP (Roach
et al., 2012). Metabolism of G6P through the PPP is used to
generate nucleotides required for sustained proliferation, as
well as NADPH, which is an important reducing agent for
nucleotide, amino acid, and lipid synthesis, and also for ROS
Figure 6. Effects of PYGL Depletion on ROS
Accumulation
(A) Transfection of U87 and MCF-7 cells with
siPYGL in normoxia significantly increases the
levels of mitochondrial superoxide compared to
scr-transfected cells, as measured by MitoSox
Red staining. Representative confocal images are
shown on the top panels, and quantification by
flow cytometry is shown on the bottom panel.
Mean ± SEM of three independent experiments is
shown (*p < 0.05, **p < 0.01).
(B) Superoxide accumulation induced by PYGL
depletion is abolished in the presence of the
superoxide dismutase mimetic MnTMPyP. Cells
where cultivated in the presence of 25 mM
MnTMPyP/DMSO for 48 hr after transfection.
Mean expression ± SEM of three independent
experiments is shown.
(C) DCF accumulation at 48 hr in normoxia,
induced by PYGL depletion in U87 cells. Mean ±
SEM of three independent experiments is shown
(*p < 0.05).
(D) The decrease in cell number induced by PYGL
knockdown in U87 cells is partially rescued when
MnTMPyP is added to the cells. Mean ± SEM of
three independent experiments is shown (*p <
0.05, ***p < 0.001).
(E) PYGL loss results in decreased levels of G6P
in MCF-7 and U87 cells. Cells were cultivated
in normoxia for 48 hr before analysis. Mean ±
SEM of three independent experiments is shown
(*p < 0.05).
(F) Depletion of PYGL is associated with increased
NADP+/NADPH ratio. MCF-7 cells were treated as
in (E). Mean ± SEM of three independent experi-
ments is shown (*p < 0.05). See also Figures S5
and S6 and Table S2.
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tion of PYGL was associated with an increase in ROS and an
arrest in proliferation, we hypothesized that the PPP could be
affected by the inability to metabolize glycogen in the absence
of PYGL. We observed a significant reduction of G6P levels in
PYGL-depleted cells (Figure 6E). This was associated withCell Metabolism 16, 751–764,a significant increase in the NADP+/
NADPH ratio in MCF-7 cells upon trans-
fection with siPYGL pool (Figure 6F).
Furthermore, our hypothesis that the
PPP activity is affected by reduced
G6P levels in PYGL-depleted cells
was confirmed by flux analysis with
D-[1,2-13C]glucose, which showed re-
duced 13C incorporation in a position
in ribose in adenosine and guanosine
nucleotides that is unique to oxidative
PPP (Figures S5D–S5F). To confirm that
reduced PPP activity is associated with
increased cell senescence, we treated
U87 cells with two specific PPP inhibitors,
6-aminonicotinamide (6-AN) and dehy-
droepiandrosterone (DHEA) (Polimeni
et al., 2011). We observed that treatmentwith either of these agents induced a significant increase in the
proportion of senescent cells (Figure S5G). We conclude that
PYGL depletion impairs the PPP pathway, due to a reduction in
intracellular G6P and hence NADPH levels.
In order to obtain a more comprehensive overview of the
metabolic changes induced by PYGL depletion (Figure S6B),December 5, 2012 ª2012 Elsevier Inc. 759
Figure 7. PYGL Knockdown Impairs Tumor Growth and Triggers Senescence
(A) PYGL knockdown in U87 cells significantly reduced tumor growth compared to control cells (left panel). 107 U87 shCtrl or U87 shPYGL cells were injected
subcutaneously in BALB/c nu/nu mice. Tumor volumes were measured every 3 days. Points represent the average size ±SEM of five to seven tumors (**p < 0.01,
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PYGL Sustains Cancer Cell Proliferationwe then performed metabolic profiling of MCF-7 siPYGL pool
versus control cells using gas chromatography-mass spec-
trometry (GC-MS) and liquid chromatography-tandem mass
spectrometry (LC-MS/MS) (Table S2 and Figure S6A). Con-
sistent with a pattern of decreased flux of G6P through the
PPP and increased ROS levels, PYGL knockdown cells ex-
hibited lower levels of 6-phosphogluconate and nucleotides,
and increased levels of oxidized glutathione (GSSG). The evalu-
ation of extracellular glucose and lactate did not show any sig-
nificant difference between PYGL knockdown and control cells
(Figure S6B).
Taken together, our data suggest that PYGL is required to
sustain cancer cell proliferation, and its absence leads to in-
creased ROS-induced premature senescence. Furthermore,
we propose that attenuation of glycogen breakdown by PYGL
depletion leads to decreased levels of G6P and NADPH, which
impair nucleotide production and ROS scavenging potential
(Figure S6C).
PYGL Knockdown Impairs the In Vivo Growth of Tumor
Xenografts
Next, we tested the effect of PYGL depletion in spheroids as
a 3D model of cancer cell growth. Both U87 and MCF-7 cells
formed spheroids. After 7 days from plating, spheroid volumes
were markedly reduced in the siPYGL pool group (8.8 ± 1.3 3
107 versus 27.0 ± 0.7 3 107 mm3 for U87 and 6.8 ± 1.0 3 107
versus 11.6 ± 0.0 3 107 mm3 for MCF-7) (Figure S7A). Growth
was also significantly reduced in spheroids derived from U87
cells with stable PYGL knockdown, and this was associated
with increased glycogen levels, as measured by PAS staining
(Figure S7B).
To test the in vivo roles of PYGL during cancer development,
U87 cells with stable PYGL knockdown or U87 control cells
were injected subcutaneously in nude mice, and tumor growth
wasmonitored. PYGL depletion resulted in a profound reduction
of tumor growth as compared to controls. In particular, at day 43
after injection, tumor volumes were 1,095 ± 250 versus 130 ±
25mm3 in the control and the PYGL knockdown groups, respec-
tively (Figure 7A). In vitro, we observed that PYGL depletion
impaired cell proliferation via the induction of senescence. To
investigate whether a similar mechanism was responsible for
tumor growth inhibition in vivo, tumors were collected at the
end of the experiment (day 43) and examined for the senes-
cence-associated markers DEC1 and p21. PYGL reduction
was associated with a significant 5-fold increase in the expres-
sion of both DEC1 (47.2% ± 3.8% versus 8.5% ± 1.1%) and
p21 (17.2% ± 2.1% versus 3.4% ± 1.1%) (Figure 7B). Impor-
tantly, U87 knockdown and control tumors had similar levels of
necrosis, excluding the possibility that this type of cell death
was contributing to tumor growth suppression in vivo (Figure 7B).
These results suggest that PYGL represents a strong candidate
for anticancer therapy.***p < 0.001). At the end of the experiment, PYGL mRNA expression was analyze
(*p < 0.05).
(B) From top to bottom: tumor histology with necrotic areas indicated by N, persis
senescencewasmeasured by staining for DEC1 and p21. Representative images
three to six fields of each tumor sample at 2003magnification were analyzed. Me
See also Figure S7.
Cell MDISCUSSION
Glycogen metabolism has recently been proposed as an impor-
tant pathway of metabolic reprogramming in cancer cells (Bra-
himi-Horn et al., 2011; Pelletier et al., 2012; Pescador et al.,
2010; Shen et al., 2010). In this study, we demonstrated an
essential role of glycogen breakdown in cancer cells. More
specifically, we report that depletion of the catabolic enzyme
PYGL resulted in glycogen accumulation that was associated
with reduced proliferation and a corresponding induction of
senescence. Our data highlight how a greater understanding of
cellular metabolism reprogramming events during tumor devel-
opment can reveal which specific metabolic pathways comprise
putative targets for anticancer therapies.
Consistent with altered glycogen turnover being a feature of
hypoxia, we observed upregulation of a number of enzymes
implicated in glycogen metabolism in vivo. The coordinated
induction of these enzymes suggests that glycogen metabolism
is functionally associated with cellular adaptation to hypoxia. As
part of our analyses, we observed characteristic signatures of
GYS1 and PYGL induction, as well as glycogen accumulation,
in response to hypoxia. Moreover, our data were consistent
with an acute induction of glycogen synthesis catalyzed by
GYS1, followed by a subsequent induction of PYGL-dependent
breakdown of glycogen. Our results provide a more comprehen-
sive analysis of the glycogen metabolism profile in hypoxia as
compared to a previous study in which only the early anabolic
response (up to 24 hr) was reported (Pescador et al., 2010).
The phenotypic consequences of disrupting glycogen break-
down were surprisingly profound, both in vitro and in vivo.
This suggests that the channeling of glucose through gly-
cogen has important implications for cell growth, and that
glycogen may possess additional physiological functions that
go beyond its role as an energy source in situations of increased
glucose demand. A similar phenomenon, whereby glucose is
incorporated into glycogen and subsequently released as G1P
even in the presence of abundant extracellular glucose, has
been described previously in brain astrocytes, and is referred
to as the ‘‘glycogen shunt’’ (Obel et al., 2012). However, the
precise reasons for this physiological response remain largely
unexplained.
We propose that the enhanced induction of senescence
following PYGL depletion occurs, at least partly, via a ROS-
dependent mechanism that leads to the activation of p53.
Evidence for this comes from our observations that the prema-
ture senescence phenotype associated with PYGL knockdown
could be partially suppressed by codepleting p53, or by adding
a ROS scavenger. Future studies will aim to test this hypothesis
also in vivo. Our flux and metabolomic analyses also revealed
that PYGL depletion led to reduced flux through the PPP, which
is important for generating NADPH, nucleotides, amino acids,
and lipids required for continued cell proliferation. A number ofd in the two groups (right panel). Mean ± SEM of five to seven tumors is shown
tence of knockdown was determined by immunostaining for PYGL, tumor cell
are shown on the left, quantification is displayed on the right. For quantification,
an expression ±SEM of five to seven tumors is shown (**p < 0.01, ***p < 0.001).
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PYGL Sustains Cancer Cell Proliferationother studies have verified the importance of GP in sustaining
continued cell proliferation. Inhibition of GP using a small mole-
cule inhibitor (CP-320626) promoted apoptosis by limiting glu-
cose oxidation, nucleic acid, and lipid synthesis in a human
pancreatic cancer cell line (Lee et al., 2004). More recently, acti-
vation of various stress-induced pathways and increased levels
of cell-cycle regulators were also reported (Ma et al., 2012). A
similar effect on cell viability was reported in human umbilical
endothelial cells treated with escalating doses of CP-320626
(Viza´n et al., 2009). However, the specificity of these results
remains to be determined, in view of the considerably higher
(more than 1,000-fold) IC50 reported by the authors, compared
to the one previously determined on purified enzyme (Oikonoma-
kos et al., 2002). Moreover, glycogen accumulation after GP inhi-
bition was not measured.
Notably, we cannot exclude the possibility that glycogen itself
fulfils important intracellular signaling functions, at least when
present at high levels. Consistent with this possibility, the induc-
tion of senescence in PYGL-depleted cells was also suppressed
by preventing GYS1-dependent glycogen accumulation. The
putative signaling functions of glycogen may arise through its
ability to directly regulate the activity of AMP-activated protein
kinase (AMPK) (McBride et al., 2009), which can lead to p53-
dependent cellular senescence if persistently activated (Jones
et al., 2005).
Collectively, we propose that glycogen degradation by PYGL
provides a source of G6P (which can maintain the reduction
of NADPH and glutathione, and the synthesis of nucleotides,
through the PPP) and limits the intracellular levels of glycogen
(that may otherwise directly contribute to the induction of senes-
cence). Therefore, in hypoxic cells lacking PYGL, glycogen
accumulation, decreased nucleotide synthesis, and increased
levels of ROS may all additively contribute to a p53-dependent
growth arrest (Figure S6C).
Taken together with our promising results obtained in vivo,
in which tumorigenesis of U87 shPYGL xenografts was signifi-
cantly impaired and tumor senescence was induced, a number
of observations have suggested that PYGL may comprise a
target for anticancer therapy. First, PYGL is one of the 99 genes
included in the hypoxia ‘‘metagene’’ that is proposed to form a
hypoxic signature with prognostic significance in HNSCC and
breast cancer (Winter et al., 2007). Furthermore, our Oncomine
search revealed increased expression of PYGL in a number of
tumor types as compared to normal tissues. Importantly, target-
ing of PYGL for cancer therapy would likely present limited side
effects, because patients affected by Hers disease, an inherited
glycogen storage disease caused by deficiency of PYGL,
present only mild symptoms during childhood, and most adults
are asymptomatic (Dagli and Weinstein, 1993). Indeed, small
molecule inhibitors of PYGL are currently under investigation
for the treatment of diabetes (Praly and Vidal, 2010). Our data
suggest that these could also warrant consideration as possible
anticancer therapies in future studies. In particular, given that
PYGL expression is increased following bevacizumab treatment
in vivo, we predict that targeting of this pathway is likely to be
more effective in tumors that are markedly hypoxic. It will be of
great interest to investigate the combined effects of PYGL inhibi-
tion and bevacizumab and to determine if PYGL is required for
resistance to antiangiogenic therapy.762 Cell Metabolism 16, 751–764, December 5, 2012 ª2012 ElsevierEXPERIMENTAL PROCEDURES
Cell Culture
The glioblastoma U87, breast cancer MCF-7, and colon cancer HCT116 cell
lines were provided by Cancer Research UK Cell Services and were grown
in high-glucose (25 mM) Dulbecco’s modified Eagle’s medium (DMEM) sup-
plemented with 10% fetal bovine serum. In a set of experiments, U87 cells
were cultivated in low glucose (5 mM) DMEM (GIBCO-BRL). Cell exposure
to hypoxia (0.1% oxygen) was undertaken in an in vivo2 400 hypoxic worksta-
tion (Ruskinn Technologies).
Glycogen Quantification
Glycogen levels were measured using the Glycogen Assay Kit (BioVision)
following manufacturer’s instructions. Briefly, cells were homogenized with
200 ml of dH2O on ice and then boiled for 5 min. Homogenates were spun at
13,000 rpm for 5 min and supernatants were assayed for glycogen content.
Results were normalized by protein content or cell number.
Periodic Acid Schiff Staining
Glycogen was detected in cells, spheroids, and tumor sections following
a standardized periodic acid Schiff (PAS) staining technique. Briefly, cells
were fixed with 4% paraformaldehyde for 15 min, incubated in 1% periodic
acid (Sigma-Aldrich) for 5 min, rinsed in water, and placed in Schiff’s reagent
(Sigma-Aldrich) for 10 min. Finally, cells were washed with water. Amylase
(Sigma-Aldrich) was used in a set of experiments to verify that staining was
specific for glycogen. Images were obtained using a Zeiss Axiovert 135
microscope.
Electron Microscopy
Cell pellets were fixed in 4%glutaraldehyde in 0.1Mphosphate buffer and pro-
cessed for routine electron microscopy (Ling et al., 2006). In summary, the
samples were postfixed in osmium tetroxide, dehydrated in ethanol, treated
with propylene oxide, and embedded in Spurr’s epoxy resin. Sections (1 mm)
were stained with Azure A for light microscopy and thin sections stained
with uranyl acetate and lead citrate prior to examination in a Jeol 1200EX elec-
tron microscope. Specific staining for polysaccharides was carried out using
an adaptation of the PATO method (Ferguson et al., 1977).
Sa-b-Gal Staining
To detect senescent cells, a Senescence Detection Kit (Calbiochem) was
used, and staining was performed according to manufacturer’s instructions.
Images were acquired with a Zeiss Axiovert 135 microscope.
Cell-Cycle Analysis
To evaluate cell-cycle distribution, cells were washed with ice-cold PBS, re-
suspended in 1 ml of PBS, and fixed by the dropwise addition of 3 ml of
100% ethanol for 20 min at 4C. Cells were washed twice with ice-cold PBS
and resuspended in a PI solution (100 mg/ml) containing DNase-free RNase
(12 mg/ml) (Sigma). After 15 min incubation at room temperature, cells were
analyzed in a FACS analyzer Cyan ADP (Dako).
ROS Detection
ROS levels were measured using either MitoSOX Red (Molecular Probes), as
an indicator of mitochondrial superoxide, or H2-DCFDA (Molecular Probes),
as an indicator of intracellular ROS. Cells were treated as appropriate and
subsequently loaded with 5 mM MitoSOX Red or H2-DCFDA for 45 min. For
microscopic analysis, cells were washed with PBS and mounted with Vecta-
Shield (Vector Laboratories) with DAPI. Images were acquired with a Zeiss
Axioskop 2 plus microscope. For flow cytometry analysis, cells were washed
and scraped in PBS and immediately analyzed in a FACS analyzer Cyan ADP.
In a set of experiments, cells were cultivated in the presence of 25 mM
MnTMPyP (Calbiochem).
Glucose-6-Phosphate and NADP+/NADPH Quantification
G6P levels and NADP+/NADPH ratio were determined with the Glucose-6-
Phosphate Assay Kit and the NADP+/NADPH Quantification Kit (both from
BioVision), respectively. Measurements were performed according to theInc.
Cell Metabolism
PYGL Sustains Cancer Cell Proliferationmanufacturer’s instruction. Results were presented as fold change in MCF-7
siPYGL pool versus MCF-7 scr.
Mouse Tumor Studies
All protocols were carried out under Home Office regulations (Li et al., 2007).
Six- to eight-week-old female BALB/c SCID or BALB/c NuNu mice (Harlan
Sprague Dawley, Inc.) were injected subcutaneously in the lower flank with
100 ml of Matrigel (BD Bioscience) and 1 3 107 cells suspended in 100 ml of
serum-free medium. Tumor growth was monitored and measured three times
per week using calipers. Tumor volume was calculated from the formula V =
L3W3H3p/6 (L = length, W =width, and H = height). When tumors reached
1.44 cm3, mice were sacrificed by cervical dislocation. Ninety minutes prior to
sacrifice, mice were injected intraperitoneally with 100 mg/kg of pimonidazole
(Hypoxyprobe-1; Chemicon International).
Tumor samples at different stages of development from the Her-2/neu trans-
genic spontaneous mouse model of breast carcinogenesis were kindly pro-
vided by S. Indraccolo (IOV-IRCCS, Padua, Italy).
Histology and Immunohistochemistry
A standard hematoxylin and eosin protocol was followed to assess the mor-
phology of HCT116 spheroids. Immunohistochemistry was carried out as
previously described (Li et al., 2007). The following primary antibodies were
used: pimonidazole (Hypoxyprobe-1; Chemicon International), GYS1 (abcam),
PYGL (Sigma-Aldrich), DEC1 (CW27), p21 (Dako), CA9 (M75). Slides were
incubated with the anti-rabbit/anti-mouse secondary antibody (Dako), and
DAB (Dako) was applied to the sections for 5–8 min. The slides were counter-
stained by immersing in hematoxylin solution (Sigma-Aldrich) and mounted
with Aquamount (VWR). Slides were scored by two researchers blinded to
grouping or analyzed quantitatively by image analysis in ImageJ using color
deconvolution as described previously (Ruifrok and Johnston, 2001).
Statistical Analyses
Statistical analysis and graphs were performed using GraphPad Prism v4.0b
software (GraphPad). Statistics were carried out using Student’s t tests and
linear regression of log-transformed growth data. Results are means + SEM,
and significance is represented by *p < 0.05, **p < 0.01, and ***p < 0.001.
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